Wall Street analysts expect that China Biologic Products (NASDAQ:CBPO) will report $1.28 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products reported earnings of $1.32 per share in the same quarter last year, which would indicate a negative year over year growth rate of 3%. The firm is scheduled to issue its next earnings results on Wednesday, May 2nd.
On average, analysts expect that China Biologic Products will report full-year earnings of $5.22 per share for the current fiscal year, with EPS estimates ranging from $5.09 to $5.34. For the next fiscal year, analysts expect that the business will report earnings of $5.84 per share, with EPS estimates ranging from $5.79 to $5.88. Zacks’ EPS averages are an average based on a survey of analysts that follow China Biologic Products.
China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.90 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.89 by $0.01. The business had revenue of $90.10 million for the quarter, compared to the consensus estimate of $85.15 million. China Biologic Products had a net margin of 18.34% and a return on equity of 21.30%. The firm’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.95 earnings per share.
A number of equities analysts recently weighed in on CBPO shares. BidaskClub upgraded shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 20th. TheStreet downgraded shares of China Biologic Products from a “b-” rating to a “c+” rating in a report on Thursday, March 1st. Zacks Investment Research downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Monday, January 29th. Jefferies Group restated a “buy” rating and set a $97.00 target price on shares of China Biologic Products in a report on Thursday, March 15th. Finally, Deutsche Bank set a $105.00 target price on shares of China Biologic Products and gave the stock a “buy” rating in a report on Friday, March 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $101.00.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in China Biologic Products during the fourth quarter worth $117,000. Legal & General Group Plc boosted its position in China Biologic Products by 41.2% during the third quarter. Legal & General Group Plc now owns 2,966 shares of the biopharmaceutical company’s stock worth $274,000 after purchasing an additional 865 shares during the period. Cubist Systematic Strategies LLC boosted its position in China Biologic Products by 73.2% during the third quarter. Cubist Systematic Strategies LLC now owns 4,617 shares of the biopharmaceutical company’s stock worth $426,000 after purchasing an additional 1,952 shares during the period. Landscape Capital Management L.L.C. boosted its position in China Biologic Products by 27.7% during the fourth quarter. Landscape Capital Management L.L.C. now owns 7,254 shares of the biopharmaceutical company’s stock worth $571,000 after purchasing an additional 1,573 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in China Biologic Products during the third quarter worth $795,000. Institutional investors and hedge funds own 56.27% of the company’s stock.
Shares of CBPO opened at $86.84 on Wednesday. The firm has a market cap of $2,813.97, a P/E ratio of 17.54, a PEG ratio of 1.29 and a beta of 1.46. China Biologic Products has a 1-year low of $71.85 and a 1-year high of $120.46.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.